Cargando…
A lower dosage of imatinib in patients with gastrointestinal stromal tumors with toxicity of the treatment
This study investigated the efficiency and safety of imatinib in the lower dose (300 mg/d) in patients with gastrointestinal stromal tumor (GIST) who cannot tolerate imatinib in the standard dose (400 mg/d). Steady-state imatinib trough concentration (Cmin) values in 18 patients with GIST who were t...
Autores principales: | Yin, Yuan, Xiang, Jin, Tang, Sumin, Chen, Jiaju, Yu, Qin, Zhang, Bo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5266004/ https://www.ncbi.nlm.nih.gov/pubmed/27930532 http://dx.doi.org/10.1097/MD.0000000000005488 |
Ejemplares similares
-
Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
por: Tang, Sumin, et al.
Publicado: (2017) -
Preoperative imatinib for patients with primary unresectable or metastatic/recurrent gastrointestinal stromal tumor
por: Shen, Chaoyong, et al.
Publicado: (2014) -
Evaluating the role of GSTP1 genetic polymorphism (rs1695, 313A>G) as a predictor in cyclophosphamide-induced toxicities
por: Gong, Jin-Yu, et al.
Publicado: (2021) -
The risk of gastrointestinal hemorrhage with non-vitamin K antagonist oral anticoagulants: A network meta-analysis
por: Oh, Hyun Jin, et al.
Publicado: (2021) -
Lower limb immobilization device induced small setup errors in the radiotherapy
por: Lu, Yuting, et al.
Publicado: (2018)